Otsuka Holdings Co., Ltd. – Unsponsored ADR (OTCMKTS:OTSKY) Short Interest Update

Otsuka Holdings Co., Ltd. – Unsponsored ADR (OTCMKTS:OTSKY) was the target of a large increase in short interest during the month of July. As of July 15th, there was short interest totaling 76,340 shares, an increase of 116.4% from the June 30th total of 35,280 shares. Currently, 0.0% of the company’s stock are sold short. Based on an average daily trading volume, of 93,500 shares, the days-to-cover ratio is currently 0.8 days.

Otsuka Stock Up 2.2%

Shares of OTCMKTS OTSKY traded up $0.77 during trading hours on Thursday, hitting $35.83. The stock had a trading volume of 43,875 shares, compared to its average volume of 39,869. The firm’s 50-day moving average price is $34.21 and its two-hundred day moving average price is $33.47. Otsuka has a 52 week low of $23.67 and a 52 week high of $37.52. The company has a market capitalization of $38.49 billion and a P/E ratio of 15.12. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.67 and a current ratio of 2.17.

Otsuka (OTCMKTS:OTSKY) last posted its earnings results on Tuesday, April 28th. The company reported $0.59 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.43 by $0.16. The firm had revenue of $3.96 billion during the quarter, compared to analysts’ expectations of $3.78 billion. Otsuka had a net margin of 15.01% and a return on equity of 12.33%. Analysts anticipate that Otsuka will post 1.96 EPS for the current fiscal year.

Otsuka Company Profile

Otsuka Pharmaceutical Co, Ltd., trading in the U.S. under the ticker OTCMKTS:OTSKY, is a global healthcare company headquartered in Tokyo, Japan. The firm’s core activities span the development, manufacturing and marketing of prescription pharmaceuticals, consumer healthcare products and nutraceuticals. Otsuka focuses its research on areas such as neuroscience, cardiovascular and renal therapies, and oncology, aiming to bring innovative treatments to patients worldwide.

Founded in 1964 by Busaburo Otsuka as a subsidiary of the Otsuka Group, the company has grown into a diversified healthcare enterprise over more than five decades.